TABLE OF CONTENTS
1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 39
1.3 OVERVIEW OF MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 39
1.4 LIMITATIONS 41
1.5 MARKETS COVERED 41
2 MARKET SEGMENTATION 44
2.1 MARKETS COVERED 44
2.2 GEOGRAPHICAL SCOPE 45
2.3 YEARS CONSIDERED FOR THE STUDY 46
2.4 CURRENCY AND PRICING 46
2.5 DBMR TRIPOD DATA VALIDATION MODEL 47
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.7 MULTIVARIATE MODELLING 51
2.8 DISTRIBUTION CHANNEL LIFELINE CURVE 51
2.9 DBMR MARKET POSITION GRID 52
2.10 VENDOR SHARE ANALYSIS 54
2.11 MARKET END USER COVERAGE GRID 55
2.12 SECONDARY SOURCES 56
2.13 ASSUMPTIONS 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 61
4.1 PORTERS FIVE FORCES 62
4.2 PESTEL ANALYSIS 63
4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES 64
4.3.1 CEPHEID 64
4.3.2 THERMO FISHER SCIENTIFIC INC. 65
4.3.3 HOLOGIC, INC. 66
4.3.4 BD 67
4.3.5 F. HOFFMANN-LA ROCHE LTD 68
4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY 69
4.5 DISTRIBUTORS 70
4.5.1 NORTH AMERICA 70
4.5.2 EUROPE 71
4.5.3 SOUTH ASIA 73
4.5.4 SOUTH EAST ASIA 74
4.5.5 MIDDLE EAST 76
4.5.6 AFRICA 77
5 REGULATORY FRAMEWORK 78
6 MARKET OVERVIEW 81
6.1 DRIVERS 83
6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES 83
6.1.2 IMPROVING DIAGNOSIS SEEKING RATE 83
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 84
6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE 84
6.1.5 RISING PREFERENCE FOR HOMECARE TESTING 85
6.2 RESTRAINTS 86
6.2.1 PRODUCT RECALLS 86
6.2.2 HIGH COSTS OF PRODUCTS 86
6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS 87
6.3 OPPORTUNITIES 87
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 87
6.3.2 RISING HEALTHCARE EXPENDITURE 88
6.3.3 PANDEMIC OUTBREAK OF COVID-19 89
6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 89
6.4 CHALLENGES 90
6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES 90
6.4.2 LACK OF ACCESSIBILITY 90
7 IMPACT OF COVID-19 ON THE MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET 92
7.1 IMPACT ON PRICE 92
7.2 IMPACT ON DEMAND 92
7.3 IMPACT ON SUPPLY CHAIN 93
7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19 93
7.5 CONCLUSION: 94
8 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT 95
8.1 OVERVIEW 96
8.2 CONSUMABLES & REAGENTS 99
8.3 INSTRUMENTS 99
8.3.1 MOBILE PLATFORM (SMALL & PORTABLE) 100
8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM) 100
9 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION 101
9.1 OVERVIEW 102
9.2 RESPIRATORY INFECTIONS TESTING 105
9.2.1 COVID-19 106
9.2.2 FLU B 106
9.2.3 FLU A 106
9.2.4 RSV 106
9.2.5 TUBERCULOSIS 106
9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA) 106
9.2.7 OTHERS 107
9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING 107
9.3.1 TV 108
9.3.2 CT 108
9.3.3 NG 108
9.3.4 HPV 108
9.3.5 HSV 108
9.3.6 MG 108
9.3.7 UU 109
9.3.8 MH 109
9.3.9 OTHERS 109
9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING 109
9.4.1 GROUP B STREPTOCOCCUS 110
9.4.2 SHIGA TOXIN 110
9.4.3 H. PYLORI 110
9.5 OTHERS 111
10 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER 112
10.1 OVERVIEW 113
10.2 LABORATORIES 116
10.2.1 POLYMERASE CHAIN REACTION 117
10.2.2 ISOTHERMAL AMPLIFICATION 117
10.3 HOSPITAL 117
10.3.1 POLYMERASE CHAIN REACTION 118
10.3.2 ISOTHERMAL AMPLIFICATION 118
10.4 CLINICS 118
10.4.1 POLYMERASE CHAIN REACTION 119
10.4.2 ISOTHERMAL AMPLIFICATION 119
10.5 AMBULATORY CENTER 119
10.5.1 POLYMERASE CHAIN REACTION 120
10.5.2 ISOTHERMAL AMPLIFICATION 120
10.6 HOMECARE 120
10.6.1 POLYMERASE CHAIN REACTION 121
10.6.2 ISOTHERMAL AMPLIFICATION 121
10.7 ASSISTED LIVING FACILITIES 122
10.7.1 POLYMERASE CHAIN REACTION 122
10.7.2 ISOTHERMAL AMPLIFICATION 122
10.8 OTHERS 123
11 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING 124
11.1 OVERVIEW 125
11.2 PRESCRIPTION-BASED TESTING 128
11.3 OTC TESTING 129
12 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL 130
12.1 OVERVIEW 131
12.2 HOSPITAL PHARMACY 134
12.3 RETAIL PHARMACY 135
12.4 ONLINE PHARMACY 136
13 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION 137
13.1 MIDDLE EAST 138
13.1.1 SAUDI ARABIA 147
13.1.2 U.A.E 152
13.1.3 ISRAEL 157
13.1.4 EGYPT 162
13.1.5 REST OF MIDDLE EAST 167
13.2 AFRICA 168
13.2.1 SOUTH AFRICA 177
13.2.2 KENYA 182
13.2.3 NIGERIA 187
13.2.4 REST OF AFRICA 192
14 MIDDLE EAST & AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE 193
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 193
15 SWOT ANALYSIS 194
16 COMPANY PROFILE 195
16.1 DANAHER 195
16.1.1 COMPANY SNAPSHOT 195
16.1.2 REVENUE ANALYSIS 195
16.1.3 COMPANY SHARE ANALYSIS 196
16.1.4 PRODUCT PORTFOLIO 196
16.1.5 RECENT DEVELOPMENTS 197
16.2 THERMO FISHER SCIENTIFIC INC. 198
16.2.1 COMPANY SNAPSHOT 198
16.2.2 REVENUE ANALYSIS 198
16.2.3 COMPANY SHARE ANALYSIS 199
16.2.4 PRODUCT PORTFOLIO 199
16.2.5 RECENT DEVELOPMENTS 199
16.3 BD 200
16.3.1 COMPANY SNAPSHOT 200
16.3.2 REVENUE ANALYSIS 200
16.3.3 COMPANY SHARE ANALYSIS 201
16.3.4 PRODUCT PORTFOLIO 201
16.3.5 RECENT DEVELOPMENTS 201
16.4 F.HOFFMANN-LA-ROCHE LTD. 202
16.4.1 COMPANY SNAPSHOT 202
16.4.2 REVENUE ANALYSIS 202
16.4.3 COMPANY SHARE ANALYSIS 203
16.4.4 PRODUCT PORTFOLIO 203
16.4.5 RECENT DEVELOPMENTS 204
16.5 ABBOTT 205
16.5.1 COMPANY SNAPSHOT 205
16.5.2 REVENUE ANALYSIS 205
16.5.3 PRODUCT PORTFOLIO 206
16.5.4 RECENT DEVELOPMENTS 206
16.6 BINX HEALTH, INC. 207
16.6.1 COMPANY SNAPSHOT 207
16.6.2 PRODUCT PORTFOLIO 207
16.6.3 RECENT DEVELOPMENT 207
16.7 BIOMERIEUX SA 208
16.7.1 COMPANY SNAPSHOT 208
16.7.2 REVENUE ANALYSIS 208
16.7.3 PRODUCT PORTFOLIO 209
16.7.4 RECENT DEVELOPMENT 209
16.8 CO-DIAGNOSTICS, INC. 210
16.8.1 COMPANY SNAPSHOT 210
16.8.2 REVENUE ANALYSIS 210
16.8.3 PRODUCT PORTFOLIO 211
16.8.4 RECENT DEVELOPMENTS 211
16.9 GENMARK DIAGNOSTICS, INC 212
16.9.1 COMPANY SNAPSHOT 212
16.9.2 REVENUE ANALYSIS 212
16.9.3 PRODUCT PORTFOLIO 213
16.9.4 RECENT DEVELOPMENT 213
16.10 GRIFOLS, S.A. 214
16.10.1 COMPANY SNAPSHOT 214
16.10.2 REVENUE ANALYSIS 214
16.10.3 PRODUCT PORTFOLIO 215
16.10.4 RECENT DEVELOPMENT 215
16.11 LUCIRA HEALTH INC. 216
16.11.1 COMPANY SNAPSHOT 216
16.11.2 PRODUCT PORTFOLIO 216
16.11.3 RECENT DEVELOPMENTS 216
16.12 MERIDIAN BIOSCIENCE 217
16.12.1 COMPANY SNAPSHOT 217
16.12.2 REVENUE ANALYSIS 217
16.12.3 PRODUCT PORTFOLIO 218
16.12.4 RECENT DEVELOPMENTS 218
16.13 QUANTUMDX GROUP LTD. 219
16.13.1 COMPANY SNAPSHOT 219
16.13.2 PRODUCT PORTFOLIO 219
16.13.3 RECENT DEVELOPMENTS 219
16.14 QUIDEL CORPORATION 221
16.14.1 COMPANY SNAPSHOT 221
16.14.2 REVENUE ANALYSIS 221
16.14.3 PRODUCT PORTFOLIO 222
16.14.4 RECENT DEVELOPMENT 222
16.15 SD BIOSENSOR, INC. 223
16.15.1 COMPANY SNAPSHOT 223
16.15.2 PRODUCT PORTFOLIO 223
16.15.3 RECENT DEVELOPMENT 223
16.16 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL) 224
16.16.1 COMPANY SNAPSHOT 224
16.16.2 PRODUCT PORTFOLIO 224
16.16.3 RECENT DEVELOPMENT 224
16.17 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION 226
16.17.1 COMPANY SNAPSHOT 226
16.17.2 REVENUE ANALYSIS 226
16.17.3 PRODUCT PORTFOLIO 227
16.17.4 RECENT DEVELOPMENT 227
16.18 WONDFO 228
16.18.1 COMPANY SNAPSHOT 228
16.18.2 PRODUCT PORTFOLIO 228
16.18.3 RECENT DEVELOPMENT 228
17 QUESTIONNAIRE 229
18 RELATED REPORTS 232

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.